Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S. manufacturing amid President Donald Trump's tariff threats.

For Matt Studney, who joined Merck as a chemical engineer, technology changed the course of his career. In 2017, the pharma giant was one of several healthcare businesses breached by a cyberattack.

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...